![]() |
市場調查報告書
商品編碼
1797676
膠原蛋白及玻尿酸關節內注射的全球市場:產品類型·用途·通路·各地區 (~2035年)Global Collagen and Hyaluronic Acid Intra-Articular Injections Market by Product Type, by Application, by Distribution Channel, and by Region Forecast till 2035 |
預計2035年,全球膠原蛋白和透明質酸關節內注射市場規模將達到63.248億美元,預測期內複合年增長率為6.15%。
透明質酸和膠原蛋白直接注射到關節中用於治療關節疾病。透明質酸被認為是理想的潤滑劑和減震劑,而膠原蛋白是由軟骨最基本的組成部分形成的,有助於軟骨結構和再生。透過減輕僵硬和疼痛,患者可以恢復失去的功能和活動能力,最終朝著避免手術邁出重要一步。
隨著製造商尋求滿足骨關節炎、類風濕性關節炎和運動傷害高發病率的需求,膠原蛋白和透明質酸正成為越來越受歡迎的解決方案。由於人口老化以及肥胖和缺乏運動等風險因素的增加,越來越多的患者選擇非手術治療。這些注射在改善關節功能和推遲昂貴的手術方面發揮關鍵作用,有助於全球市場穩定成長。
北美佔全球市場收入的大部分,這得益於患者教育水平的提高和關節內注射藥物的早期應用。美國在北美膠原蛋白和透明質酸關節內注射市場中處於領先地位,市場規模達到12.1126億美元,其次是加拿大,市場規模為1.7035億美元,顯示該地區市場需求強勁。由於全面的保險覆蓋和一致的臨床療效,這些治療在美國市場具有很高的可及性。
在歐洲,由於人口預期壽命的提高和對先進治療的需求,市場規模持續擴大。德國以1.3061億美元領先歐洲市場,其次是英國(9,489萬美元)和法國(8,334萬美元)。憑藉廣泛的研究和完善的醫療保健網絡,德國和法國佔了大部分市場佔有率。
亞太地區潛力巨大,人口眾多的國家需求激增。中國以1.2742億美元的市場規模位居亞太地區首位,其次是印度(8396萬美元),這兩個國家都對亞太地區的成長起到了推動作用。日本快速發展的科技生態系統有力地支持了創新,而中國龐大的患者群體則推動了市場規模的成長。
本報告探討了全球膠原蛋白和透明質酸關節內注射市場,包括市場定義和概述、影響市場成長的各種因素分析、市場規模趨勢和預測、按細分市場、地區和主要國家/地區進行的細分、競爭格局以及主要公司的概況。
Global Collagen and Hyaluronic Acid Intra-Articular Injections Market by Product Type [Hyaluronic Acid Injection (Single Injection, Multiple Injection), Collagen Injection, Combination of Hyaluronic Acid and Collagen], by Application (Knee Osteoarthritis, Joint Pains, Veterinary Applications, Post-Operative Recovery, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035
Industry Overview
The global collagen and hyaluronic acid intra-articular injections market is projected to expand at a 6.15% CAGR, reaching an estimated value of USD 6,324.80 million by 2035. Hyaluronic acid and collagen are injected directly into joints to treat joint disorders. While hyaluronic acid is expected to be the perfect lubricant and shock absorber, collagen, formed of the most basic unit of cartilage, supports the cartilage structure and regeneration. To reduce the stiffness and pain, the patients get back their lost functions and mobility, and this becomes a great step towards the final idea of surgery discontinuance.
Manufacturers are seeking to supply the demand that comes from the high rate of Osteoarthritis, Rheumatoid Arthritis, and sports injuries affecting the joint, and collagen and hyaluronic acid are becoming more and more popular as the solution. Due to the aging of the population and proliferating risk factors like obesity and inactivity, patients tend to decide in favor of non-surgical therapies. These injections have a major role in enhancing the function of the joints and in postponing expensive surgeries, which is the reason for their steady market growth all over the world.
Key Company Development
Ono Pharmaceutical and Seikagaku Corporation have succeeded in reaching a new summit in May 2021 by releasing in Japan JOYCLU 30mg Intra-articular Injection (generic: diclofenac etalhyaluronate sodium), which is a new product. By using their own technology for the binding of hyaluronic acid and diclofenol, Seikagaku has produced a unique drug that not only provides better lubrication but also fights inflammation. Consequently, JOYCLU improves the performance of the joint and resolves the problem of treatment of osteoarthritis, which is an advanced disease in Japan due to the country's aging society issue. In the wake of this event, Seikagaku has decided to introduce the new product line, starting with HyLink, in August 2021. It was conceived as the most recent single-injection viscosupplement for knee osteoarthritis with the aim of simplifying treatment by cutting down the number of injections while delivering sustained relief. In this way, the company affirms not only the needs of the patients but also its commitment to the effectiveness of clinical practice and innovation in musculoskeletal care.
Major players in the global collagen and hyaluronic acid intra-articular injection market are Seikagaku Corporation, Bioventus, Inc., Anika Therapeutics, Inc., Zimmer Biomet, Sanofi, Fidia Farmaceutici S.p.A., Teva Pharmaceutical Industries Ltd., Ferring B.V., Dr. Reddy's Laboratories Ltd., Semical Biosurgery, Avanos Medical, Inc., and Maxigen Biotech Inc. (MBI).
Report Attribute Details
Market Size 2024 USD 3,046.46 Million
Market Size 2035 USD 6,324.80 Million
CAGR (2025-2035) 6.15%
Base Year 2024
Market Forecast Period 2025-2035
Historical Data 2019-2024
By Product Type: Hyaluronic acid Injection - 6.34%, Collagen Injection - 5.45%.
By Application: Knee Osteoarthritis - 6.52%, Joint Pains - 5.74%.
By Distribution Channel: Hospital Pharmacies - 6.37%, Retail Pharmacies - 5.36%.
North America captures most of the global earnings mainly due to the high level of patient education and the early introduction of intra-articular drugs. The U.S. dominates North America's collagen and hyaluronic acid intra-articular injections market at USD 1,211.26 million, with Canada ranking second at USD 170.35 million, highlighting the region's strong demand. Supported by substantial insurance coverage and consistent clinical improvement results, the U.S. market has great accessibility to these treatments.
In Europe, the market expansion continues to be supported by the longer life expectancy of the population and their demand for sophisticated therapies. Germany leads Europe's market at USD 130.61 million, with the UK (USD 94.89 million) and France (USD 83.34 million) following as other key contributors. Germany and France are the two countries that account for the largest part of the market due to the extensive research that has been carried out and the well-established medical networks.
The Asia-Pacific region is full of potential, and thus, the demand is booming in the heavily populated countries. China holds the largest share in Asia-Pacific with USD 127.42 million, whereas India follows with USD 83.96 million, together shaping regional growth.Japan's high-speed technological ecosystem is very supportive of innovation, and China's vast patient pool drives volume growth.
Latin America's market outlook is positive but uneven, with Brazil spearheading adoption due to private healthcare investments. Market expansion is slower in smaller economies due to limited awareness and constrained spending capacity.
The Middle East & Africa market is gradually strengthening with rising demand for orthopedic care. Gulf countries, supported by government-funded health programs, are early adopters of advanced injections. African nations face structural barriers, with access concentrated in urban areas.